A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
This study tests a brand-new experimental drug called BBO-10203, either alone or with other cancer medicines, to see how safe it is. It is designed for adults with advanced solid tumors, such as specific types of breast, lung, or colorectal cancer that have spread.
You may be able to join if you have advanced breast cancer, colorectal cancer, or lung cancer with certain genetic traits that have not responded well to standard treatments. Participants also need to be well enough to carry out daily light physical activities.
You will receive the new study drug BBO-10203, and in some groups, it will be combined with other standard anti-cancer treatments or drugs. Doctors will closely monitor your health, how your body processes the medicine, and how your tumor responds through regular check-ups and scans.
This study is currently recruiting participants at medical centers in California, including Duarte, Los Angeles, and San Diego. Joining is completely voluntary, and you can talk to your care team to see if it is a good fit.
- 1Evaluates the safety of a new drug called BBO-10203 for advanced cancers.
- 2Open to adults with specific types of advanced breast, lung, or colorectal cancer.
- 3Currently recruiting patients at multiple locations in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.